Management of Persistent Neurological Symptoms After Vectorborne Infections

Assessment and Treatment

For patients with persistent moderate neurological manifestations after completing 30 days of doxycycline for vectorborne infections, the next best step is to initiate intravenous ceftriaxone at 2 g once daily for 14-28 days, as recommended by the Infectious Diseases Society of America 1, 2
The patient has completed 30 days of doxycycline without improvement in neurological symptoms, such as tinnitus, blurry vision, and memory impairment affecting activities of daily living, suggesting inadequate treatment of neurological Lyme disease or possible co-infection with other tick-borne pathogens 1, 3
The persistence of symptoms for an extended period before diagnosis and continued symptoms after initial treatment suggests either inadequate treatment or possible co-infection, highlighting the need for thorough evaluation and targeted therapy 1, 2, 3, 4

Intravenous ceftriaxone 2 g once daily is the preferred parenteral regimen for neurological manifestations of Lyme disease, with a duration of 14-28 days depending on severity and duration of symptoms, as recommended by the Infectious Diseases Society of America 1, 2, 3, 4
Alternative parenteral options if ceftriaxone is contraindicated include cefotaxime 2 g IV every 8 hours or penicillin G 18-24 million units per day IV divided every 4 hours 2
Consider testing for Babesia microti and Anaplasma phagocytophilum, especially with persistent symptoms, and add specific targeted therapy if co-infections are identified, as recommended by the Centers for Disease Control and Prevention 2, 5

Oral antibiotics, including doxycycline, may be insufficient for neurological manifestations, especially those that persist after initial therapy, due to limited CNS penetration 3, 4
Ceftriaxone has superior CNS penetration compared to oral agents, making it a preferred option for neurological manifestations of Lyme disease 1, 4
Clinical trials have demonstrated efficacy of parenteral therapy for neurologic Lyme disease when oral therapy has failed, supporting the use of intravenous ceftriaxone in these cases 4, 7

Response to treatment for late neurologic manifestations is typically slow and may be incomplete, emphasizing the need for close monitoring and adjustment of therapy as needed 4
The presence of multiple neurological symptoms suggests CNS involvement requiring more aggressive therapy, and patients with a history of neuroborreliosis who have incomplete resolution of symptoms should be evaluated for possible co-infections 3, 4

Continuing oral therapy when it has already proven ineffective is not recommended, and long-term antibiotic therapy beyond recommended durations has not shown benefit in controlled trials and is not recommended 1, 4, 6
Failure to consider co-infections can lead to persistent symptoms despite appropriate therapy for Lyme disease, highlighting the importance of thorough evaluation and targeted therapy 2